After Lucentis, Formycon also wants to launch biosimilars for Stelara and the eye drug Eylea by the middle of the decade.
Frankfurt It is not only the research into fundamentally new drugs that offers potential for up-and-coming biotech companies, but also the development of biosimilars, i.e. inexpensive copies of established biotech active ingredients.
With this strategy, the Munich-based biotech company Formycon now sees itself facing a transformation that will be shaped by two factors: firstly, the prospect of the first product approval. Regulatory authorities in the US and Europe are expected to decide on the first biosimilar to the eye drug Lucentis developed by Formycon in the summer.
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue